Enliven Therapeutics Files Q1 2025 10-Q
Ticker: ELVN · Form: 10-Q · Filed: May 14, 2025 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Enliven Therapeutics (formerly IMARA) filed Q1 2025 10-Q. Financials updated.
AI Summary
Enliven Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as IMARA Inc., reported financial information for the first quarter of 2025. Key financial data includes details on common stock, employee stock options, and fair value measurements. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides investors with an update on Enliven Therapeutics' financial health and operational status for the first quarter of 2025, crucial for understanding its current market position.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Enliven Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (Financials for the first quarter of 2025 are detailed.)
- 1231 — Fiscal Year End (Indicates the end of the company's annual financial reporting cycle.)
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Filer of the 10-Q
- IMARA Inc. (company) — Former name of Enliven Therapeutics, Inc.
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- DE (location) — State of incorporation
FAQ
What was Enliven Therapeutics' former company name?
Enliven Therapeutics, Inc. was formerly known as IMARA Inc.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 14, 2025.
In which state is Enliven Therapeutics, Inc. incorporated?
Enliven Therapeutics, Inc. is incorporated in Delaware (DE).
What is the SIC code for Enliven Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Enliven Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Enliven Therapeutics, Inc. (ELVN).